1. An, S. J., Huang, Y. S., Chen, Z. H., Su, J., Yang, Y., Chen, J. G., Yan, H. H., Lin, Q. X., Yang, J. J., Yang, X. N., Zhou, Q., Zhang, X. C., & Wu, Y. L. (2012). Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Medical Oncology, 29(2), 627–632.
2. Beinert, T., Binder, D., Oehm, C., Ziemer, S., Priem, F., Schweigert, M., Stuschke, M., Fleischhacker, M., Siebert, G., Mergenthaler, H. G., Werner, T. G., Sezer, O., & Possinger, K. (1999). Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumor activity and oxidative stress due to radio-chemotherapy? European Journal of Medical Research, 4(8), 328–334.
3. Berse, B., Brown, L. F., Van de Water, L., Dvorak, H. F., & Senger, D. R. (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Molecular Biology of the Cell, 3(2), 211–220.
4. Chorostowska-Wynimko, J., Zaleska, J., Chabowski, M., Szpechcinski, A., Zych, J., Rudzinski, P., Langfort, R., Orlowski, T., & Roszkowski-Sliz, K. (2009). Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer. European Journal of Medical Research, 14(Suppl 4), 42–44.
5. Dowell, J. E., Amirkhan, R. H., Lai, W. S., Frawley, W. H., & Minna, J. D. (2004). Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Research, 24(4), 2367–2373.